• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Greenbrier, Fortress Biotech And 3 Stocks To Watch Heading Into Monday

    7/8/24 3:10:02 AM ET
    $FBIO
    $GBX
    $NWGL
    $SAH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Railroads
    Industrials
    Get the next $FBIO alert in real time by email

    With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:

    • Wall Street expects The Greenbrier Companies, Inc. (NYSE:GBX) to report quarterly earnings at $1.14 per share on revenue of $928.73 million before the opening bell. Greenbrier shares gained 0.72% to $48.91 in the after-hours trading session.
    • Nature Wood Group Limited (NASDAQ:NWGL) said Jianjun Zeng is stepping down as CEO due to health reasons. The company named Hubei Song as its new CEO. Nature Wood Group shares gained 2% to $2.03 in after-hours trading.
    • Fortress Biotech, Inc. (NASDAQ:FBIO) reported a pause in the payment of dividends on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock. Fortress Biotech shares fell 2.8% to $1.75 in the after-hours trading session.

    Check out our premarket coverage here

    • Sonic Automotive, Inc. (NYSE:SAH) disclosed a cybersecurity incident impacting its dealer management and CRM systems. Sonic Automotive shares slipped 0.3% to $52.00 in after-hours trading.
    • Unicycive Therapeutics, Inc. (NASDAQ:UNCY) filed for the resale of up to 50 million shares by the selling stockholders. Unicycive Therapeutics shares fell 2% to $0.4480 in the after-hours trading session.

    Check This Out: How To Earn $500 A Month From Nvidia Stock

    Photo courtesy: The Greenbrier Company

    Get the next $FBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FBIO
    $GBX
    $NWGL
    $SAH

    CompanyDatePrice TargetRatingAnalyst
    Sonic Automotive Inc.
    $SAH
    4/23/2025$64.00Neutral
    Citigroup
    Unicycive Therapeutics Inc.
    $UNCY
    4/21/2025$6.00Buy
    Guggenheim
    Sonic Automotive Inc.
    $SAH
    3/19/2025$100.00 → $93.00Buy
    Needham
    Sonic Automotive Inc.
    $SAH
    11/22/2024$74.00Neutral → Buy
    Seaport Research Partners
    Sonic Automotive Inc.
    $SAH
    9/25/2024$40.00 → $58.00Underweight → Equal-Weight
    Morgan Stanley
    Sonic Automotive Inc.
    $SAH
    9/12/2024$64.00Equal-Weight
    Stephens
    Sonic Automotive Inc.
    $SAH
    8/20/2024$73.00Buy
    Needham
    Sonic Automotive Inc.
    $SAH
    8/6/2024$58.00 → $63.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $FBIO
    $GBX
    $NWGL
    $SAH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Greenbrier Announces Ted Baun as Next Chief Commercial Officer

      Joins Greenbrier with 30 years of rail industry experience Assumes Chief Commercial Officer role in January 2026 LAKE OSWEGO, Ore., May 21, 2025 /PRNewswire/ -- The Greenbrier Companies, Inc. (NYSE:GBX) (Greenbrier), a leading international supplier of equipment and services to global freight transportation markets, announced today that Ted Baun has joined Greenbrier's North American Commercial Team as Senior Vice President (SVP). He will become Chief Commercial Officer in January 2026, succeeding Tim Schitter, who will retire at year-end.  Baun brings more than 30 years of ex

      5/21/25 4:38:00 PM ET
      $GBX
      Railroads
      Industrials
    • Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

      LOS ALTOS, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY) ("Unicycive" or the "Company"), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced a change in the time of the 2025 Annual Meeting of Stockholders (the "Annual Meeting"). The previously announced date of the meeting (June 9, 2025) and location of the meeting (4300 El Camino Real, Suite 210, Los Altos, CA 94022) will not change, but the meeting will be held at 7:00 a.m., Pacific Daylight Time, on that date. Stockholders of record as of the close of business on April 30, 2025, the record date, can find additional details regarding participa

      5/21/25 7:00:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sonic Automotive Announces First Motorcycle Sale at the New Sturgis Harley-Davidson Dealership in Historic Downtown Sturgis, South Dakota

      The dealership is announcing an inaugural Founders Club in celebration of its grand opening and to welcome in the 85th Annual Sturgis Rally Sonic Automotive, Inc. ("Sonic'' or the "Company") ((SAH), a Fortune 300 Company and one of the nation's largest automotive and powersports retailers, today announced the first motorcycle sale at its all-new Sturgis Harley-Davidson dealership located in the heart of downtown Sturgis, South Dakota. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520529498/en/Dan Ostermann from Keystone, South Dakota, with his 2024 Harley-Davidson® CVO Pan America®, Tim Sutherland, Sales Manager, Sturgis Ha

      5/20/25 6:55:00 AM ET
      $SAH
      Retail-Auto Dealers and Gas Stations
      Consumer Discretionary

    $FBIO
    $GBX
    $NWGL
    $SAH
    Leadership Updates

    Live Leadership Updates

    See more
    • Greenbrier Announces Ted Baun as Next Chief Commercial Officer

      Joins Greenbrier with 30 years of rail industry experience Assumes Chief Commercial Officer role in January 2026 LAKE OSWEGO, Ore., May 21, 2025 /PRNewswire/ -- The Greenbrier Companies, Inc. (NYSE:GBX) (Greenbrier), a leading international supplier of equipment and services to global freight transportation markets, announced today that Ted Baun has joined Greenbrier's North American Commercial Team as Senior Vice President (SVP). He will become Chief Commercial Officer in January 2026, succeeding Tim Schitter, who will retire at year-end.  Baun brings more than 30 years of ex

      5/21/25 4:38:00 PM ET
      $GBX
      Railroads
      Industrials
    • Sonic Automotive Announces First Motorcycle Sale at the New Sturgis Harley-Davidson Dealership in Historic Downtown Sturgis, South Dakota

      The dealership is announcing an inaugural Founders Club in celebration of its grand opening and to welcome in the 85th Annual Sturgis Rally Sonic Automotive, Inc. ("Sonic'' or the "Company") ((SAH), a Fortune 300 Company and one of the nation's largest automotive and powersports retailers, today announced the first motorcycle sale at its all-new Sturgis Harley-Davidson dealership located in the heart of downtown Sturgis, South Dakota. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520529498/en/Dan Ostermann from Keystone, South Dakota, with his 2024 Harley-Davidson® CVO Pan America®, Tim Sutherland, Sales Manager, Sturgis Ha

      5/20/25 6:55:00 AM ET
      $SAH
      Retail-Auto Dealers and Gas Stations
      Consumer Discretionary
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    $GBX
    $NWGL
    $SAH
    Financials

    Live finance-specific insights

    See more
    • Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Admin

      5/14/25 4:01:35 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

      - Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 - New data from patient surveys and patient-reported outcomes studies highlight adherence challenges for patients with hyperphosphatemia on dialysis and emphasize the market potential of OLC LOS ALTOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial

      5/14/25 7:15:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

      UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2025, and recent corporate updates. Recent Corporate Updates: In December 2024, Checkpoint announced that the U.S. Food and Drug Administration ("FDA") approved UNLOXCYT™ (cosibelimab-ipdl) for the tr

      5/13/25 4:15:51 PM ET
      $CKPT
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    $GBX
    $NWGL
    $SAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $FBIO
    $GBX
    $NWGL
    $SAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Citigroup initiated coverage on Sonic Automotive with a new price target

      Citigroup initiated coverage of Sonic Automotive with a rating of Neutral and set a new price target of $64.00

      4/23/25 9:19:12 AM ET
      $SAH
      Retail-Auto Dealers and Gas Stations
      Consumer Discretionary
    • Guggenheim initiated coverage on Unicycive Therapeutics with a new price target

      Guggenheim initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $6.00

      4/21/25 8:39:22 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Sonic Automotive with a new price target

      Needham reiterated coverage of Sonic Automotive with a rating of Buy and set a new price target of $93.00 from $100.00 previously

      3/19/25 8:00:35 AM ET
      $SAH
      Retail-Auto Dealers and Gas Stations
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

      SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      11/14/24 7:13:38 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

      SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      11/14/24 7:01:14 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

      SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      11/14/24 5:46:12 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    $GBX
    $NWGL
    $SAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Williams Kelly Marie

      4 - GREENBRIER COMPANIES INC (0000923120) (Issuer)

      5/14/25 4:39:53 PM ET
      $GBX
      Railroads
      Industrials
    • Director Teramoto Wendy L was granted 16 shares, increasing direct ownership by 0.05% to 34,333 units (SEC Form 4)

      4 - GREENBRIER COMPANIES INC (0000923120) (Issuer)

      5/14/25 4:39:45 PM ET
      $GBX
      Railroads
      Industrials
    • SEC Form 4 filed by Director Huffines James R

      4 - GREENBRIER COMPANIES INC (0000923120) (Issuer)

      5/14/25 4:39:27 PM ET
      $GBX
      Railroads
      Industrials

    $FBIO
    $GBX
    $NWGL
    $SAH
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Unicycive Therapeutics Inc.

      DEFA14A - Unicycive Therapeutics, Inc. (0001766140) (Filer)

      5/21/25 9:19:29 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)

      5/21/25 9:17:38 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.

      SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      5/15/25 4:56:41 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    $GBX
    $NWGL
    $SAH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT, CEO & CHAIRMAN Rosenwald Lindsay A Md bought $1,404,581 worth of shares (763,359 units at $1.84), increasing direct ownership by 26% to 3,657,264 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      9/25/24 4:45:04 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO & Chairman Rosenwald Lindsay A Md bought $37,418 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (5,000 units at $7.48), increasing direct ownership by 4% to 127,500 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      7/15/24 4:05:14 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Jin David bought $3,750 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (500 units at $7.50) (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      7/12/24 8:42:21 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care